$1.95B
Series C Valuation, Sep 2024
Buy and sell Generate:Biomedicines stockLearn more about Generate:Biomedicines IPO
| Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
|---|---|---|---|---|---|---|
| 09/24/2024 | Series C | $288MM | $xx.xx | $1.95B | Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Fidelity, Flagship Pioneering, Maps Capital, March Capital, Novartis, Nventures, Pictet Alternative Advisors, T. Rowe Price | |
|
Price per Share
$xx.xx
Shares Outstanding
24,303,797
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Fidelity, Flagship Pioneering, Maps Capital, March Capital, Novartis, Nventures, Pictet Alternative Advisors, T. Rowe Price
|
||||||
| 11/18/2021 | Series B | $373.42MM | $xx.xx | $1.52B | Alaska Permanent Fund, Altitude Life Science Ventures, Arch Venture Partners, Flagship Pioneering, T. Rowe Price | |
|
Price per Share
$xx.xx
Shares Outstanding
31,512,642
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alaska Permanent Fund, Altitude Life Science Ventures, Arch Venture Partners, Flagship Pioneering, T. Rowe Price
|
||||||
| 09/10/2020 | Series A | $40.25MM | $xx.xx | $89.44MM | Flagship Pioneering | |
|
Price per Share
$xx.xx
Shares Outstanding
40,250,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|
||||||
| Last Funding Round | ||||||||
|---|---|---|---|---|---|---|---|---|
| Company | Forge Price | Forge Price Change 5 | Last Closed Trade | Share Class | Post-Money Valuation | Price per Share | Amount Raised | |
 | Affinia Therapeutics | -- | -- | $xx.xx | Series B | $365.7MM | $xx.xx | $110MM |
 | Altos Labs | -- | -- | $xx.xx | Series C | $6.33B | $xx.xx | $1.5B |
 | ArsenalBio | -- | -- | $xx.xx | Series C | $1.66B | $xx.xx | $327.5MM |
 | Colossal Biosciences | -- | -- | $xx.xx | Series C | $10.2B | $xx.xx | $200MM |
 | Egenesis | -- | -- | $xx.xx | Series D | $332.59MM | $xx.xx | $90.96MM |
 | Isomorphic Labs | -- | -- | $xx.xx | -- | -- | -- | -- |
 | Loyal | -- | -- | $xx.xx | Series B-5 | $428.44MM | $xx.xx | $17.49MM |
 | Owkin | -- | -- | $xx.xx | Series B-1 | $1.46B | $xx.xx | $50MM |
 | Precision Neuroscience | -- | -- | $xx.xx | Series C | $542.69MM | $xx.xx | $102MM |
 | Xaira Therapeutics | -- | -- | $xx.xx | Series A | $2.65B | $xx.xx | $500MM |
Updated on: Jan 17, 2025
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.